Company Filing History:
2 out of 2 
1 out of 934 
Years Active: 2023-2024
Title: The Innovative Contributions of Tobias Abel
Introduction
Tobias Abel is a notable inventor based in Antibes, France. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors. With a total of two patents to his name, his work focuses on advancing therapeutic options for autoimmune and inflammatory diseases.
Latest Patents
Abel's latest patents include a chimeric antigen receptor specific for the interleukin-23 receptor. This invention relates to a CAR that targets the IL-23 receptor and includes a nucleic acid encoding the receptor. It also encompasses T cells expressing this CAR, which can be utilized for treating autoimmune and inflammatory disorders. Another significant patent is for anti-HLA-A2 antibodies, which includes a novel anti-HLA-A2 antibody and a chimeric antigen receptor that incorporates this antibody. This invention is aimed at therapeutic applications, particularly in preventing graft rejection or graft-versus-host disease (GVHD).
Career Highlights
Throughout his career, Tobias Abel has worked with prominent organizations such as Sangamo Therapeutics France and the University of British Columbia. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects.
Collaborations
Abel has collaborated with notable colleagues, including François Meyer and Julie Gertner-Dardenne. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Tobias Abel's innovative work in the field of biotechnology, particularly through his patents, showcases his commitment to improving therapeutic options for patients. His contributions are significant in the ongoing fight against autoimmune and inflammatory diseases.